For instance one early study showed that low serum ApoA-II was a marker of atheroprotection in patients with non-insulin-dependent-diabetes mellitus (46) but conversely another study showed that elevated levels of ApoA-II were proatherogenic (47). This evidence concerns the gene APOA2 and type 1 diabetes mellitus.